API Regulatory Compliance & Bulk Peptide Sourcing

We provide B2B procurement teams and distributors with comprehensive oversight of the evolving pharmaceutical landscape. Our team monitors the shifting regulatory frameworks governing Active Pharmaceutical Ingredients (APIs), including FDA Section 503A bulk drug substance evaluations.

By tracking substances as they transition between FDA Categories 1 and 2, we support your organization’s risk assessment, vendor qualification, and supply continuity planning. We specialize in providing high-purity, human-grade APIs for research and development, ensuring all documentation and availability align with current jurisdictional requirements. As the regulatory status of key peptides evolves, we ensure your laboratory or manufacturing facility is prepared for upcoming market shifts and expanded sourcing opportunities.

Our B2B manufacturing services prioritize transparency and compliance in the complex peptide market. We provide dedicated monitoring of the FDA’s "Bulk Drug Substances Under Evaluation" lists to help partners navigate the transition of molecules through Category 1 and Category 2 designations.

Current Regulatory Tracking: We maintain readiness for the potential reclassification of key molecular compounds from Category 2 (restricted status) back to Category 1 (available for compounding evaluation). Our procurement support covers the 14 high-priority peptides currently under policy review, including:

• Regenerative Sequences: BPC-157, Thymosin Beta-4 (TB-500), GHK-Cu
• Metabolic & Growth Research: Ipamorelin, AOD-9604, CJC-1295, Tesamorelin
• Neuro-Biochemical Compounds: Selank, Semax, Epitalon, DSIP
• Cellular & Hormonal Signaling: MOTS-c, Kisspeptin-10, KPV

Compliance Note: Availability is dependent on the current local and federal status. We provide full COAs (Certificates of Analysis) and cGMP documentation to support your vendor qualification and risk-management protocols.